MC is already available to patients under the Special Access Scheme for the treatment of pain in chronic conditions (such as cancer etc). Substantial clinical trials have already been undertaken overseas on MC use with numerous successful end points achieved.
The science is not the issue here. It is the TGA approving products for their function and then permitting access to those products based on doctor requests. The sooner we have the finished final form product that delivers a stable and controlled dosage, the sooner product approval can be secured.
Request approval for MC under the SAS has been growing fast. It's a boom medical field.
A breakdown of the number of SAS Category B approvals by month for the previous 12 months, a 1800% increase or so YoY :
Month
Number of SAS Category B approvals
1
February 2018
37
2
March 2018
54
3
April 2018
89
4
May 2018
132
5
June 2018
146
6
July 2018
188
7
August 2018
229
8
September 2018
237
9
October 2018
331
10
November 2018
567
11
December 2018
491
12
January 2019
672
AC8 Price at posting:
43.5¢ Sentiment: None Disclosure: Held